Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Masanori Funabashi"'
Autor:
Ina Nemet, Masanori Funabashi, Xinmin S. Li, Mohammed Dwidar, Naseer Sangwan, Sarah M. Skye, Kymberleigh A. Romano, Tomas Cajka, Brittany D. Needham, Sarkis K. Mazmanian, Adeline M. Hajjar, Federico E. Rey, Oliver Fiehn, W. H. Wilson Tang, Michael A. Fischbach, Stanley L. Hazen
Publikováno v:
mBio, Vol 14, Iss 6 (2023)
ABSTRACTp-Cresol sulfate (pCS) and indoxyl sulfate (IS), gut microbiome-derived metabolites, are traditionally associated with cardiovascular disease (CVD) risks in the setting of impaired kidney function. While pharmacologic provision of pCS or IS c
Externí odkaz:
https://doaj.org/article/b42c9dbc2abc4d00ac418c59c42a7a26
Autor:
Kazuhiko Nakagawa, Kazuto Nishio, Takashi Kagari, Kenji Hirotani, Yuuri Hashimoto, Masanori Funabashi, Ryoto Yoshimoto, Maki Kobayashi, Hiroaki Okida, Eri Otsuka, Hiroki Goto, Asuka Tsuya, Yasutaka Chiba, Kazuko Sakai, Hidetoshi Hayashi, Kaoru Tanaka, Hisato Kawakami, Koji Haratani, Osamu Maenishi, Junko Tanizaki, Kimio Yonesaka
Supplementary Table from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::193a3c11e4e3e804b1cd4a8031602911
https://doi.org/10.1158/1078-0432.22487915.v1
https://doi.org/10.1158/1078-0432.22487915.v1
Autor:
Kazuhiko Nakagawa, Kazuto Nishio, Takashi Kagari, Kenji Hirotani, Yuuri Hashimoto, Masanori Funabashi, Ryoto Yoshimoto, Maki Kobayashi, Hiroaki Okida, Eri Otsuka, Hiroki Goto, Asuka Tsuya, Yasutaka Chiba, Kazuko Sakai, Hidetoshi Hayashi, Kaoru Tanaka, Hisato Kawakami, Koji Haratani, Osamu Maenishi, Junko Tanizaki, Kimio Yonesaka
Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::318557b3f697f81f5990207a8834d461
https://doi.org/10.1158/1078-0432.22487939.v1
https://doi.org/10.1158/1078-0432.22487939.v1
Autor:
Kazuhiko Nakagawa, Kazuto Nishio, Takashi Kagari, Kenji Hirotani, Yuuri Hashimoto, Masanori Funabashi, Ryoto Yoshimoto, Maki Kobayashi, Hiroaki Okida, Eri Otsuka, Hiroki Goto, Asuka Tsuya, Yasutaka Chiba, Kazuko Sakai, Hidetoshi Hayashi, Kaoru Tanaka, Hisato Kawakami, Koji Haratani, Osamu Maenishi, Junko Tanizaki, Kimio Yonesaka
Purpose:EGFR-tyrosine kinase inhibitor (TKI) is a standard first-line therapy for activated EGFR-mutated non–small cell lung cancer (NSCLC). Treatment options for patients with acquired EGFR-TKI resistance are limited. HER3 mediates EGFR-TKI resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c6ed051d8ae4eb6ca20cb9d295f077e
https://doi.org/10.1158/1078-0432.c.6532610.v1
https://doi.org/10.1158/1078-0432.c.6532610.v1
Autor:
Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Yasutaka Chiba, Asuka Tsuya, Hiroki Goto, Eri Otsuka, Hiroaki Okida, Maki Kobayashi, Ryoto Yoshimoto, Masanori Funabashi, Yuuri Hashimoto, Kenji Hirotani, Takashi Kagari, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Clinical Cancer Research. 28:390-403
Purpose: EGFR-tyrosine kinase inhibitor (TKI) is a standard first-line therapy for activated EGFR-mutated non–small cell lung cancer (NSCLC). Treatment options for patients with acquired EGFR-TKI resistance are limited. HER3 mediates EGFR-TKI resis
Autor:
Yijun Zhu, Mohammed Dwidar, Ina Nemet, Jennifer A. Buffa, Naseer Sangwan, Xinmin S. Li, James T. Anderson, Kymberleigh A. Romano, Xiaoming Fu, Masanori Funabashi, Zeneng Wang, Pooja Keranahalli, Shawna Battle, Aaron N. Tittle, Adeline M. Hajjar, Valentin Gogonea, Michael A. Fischbach, Joseph A. DiDonato, Stanley L. Hazen
Publikováno v:
Cell Host & Microbe. 31:18-32.e9
Recent studies show gut microbiota-dependent metabolism of dietary phenylalanine into phenylacetic acid (PAA) is critical in phenylacetylglutamine (PAGln) production, a metabolite linked to atherosclerotic cardiovascular disease (ASCVD). Accordingly,
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1867:22-27
Phenotype-based drug discovery is a key strategy for small molecule drug screening, and the molecular target identification of small molecules, termed "target deconvolution," is critical albeit challenging. In this review, we classify approaches for
Autor:
Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Yasutaka Chiba, Hiroki Goto, Eri Otsuka, Hiroaki Okida, Maki Kobayashi, Ryoto Yoshimoto, Masanori Funabashi, Yuuri Hashimoto, Kenji Hirotani, Takashi Kagari, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Journal of Clinical Oncology. 40:e21175-e21175
e21175 Background: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is a standard first-line therapy for activated EGFR-mutated non-small-cell lung cancer (NSCLC). Treatment options for patients with acquired EGFR-TKI resistance
Autor:
Brittany D. Needham, Masanori Funabashi, Mark D. Adame, Zhuo Wang, Joseph C. Boktor, Jillian Haney, Wei-Li Wu, Claire Rabut, Mark S. Ladinsky, Son-Jong Hwang, Yumei Guo, Qiyun Zhu, Jessica A. Griffiths, Rob Knight, Pamela J. Bjorkman, Mikhail G. Shapiro, Daniel H. Geschwind, Daniel P. Holschneider, Michael A. Fischbach, Sarkis K. Mazmanian
Publikováno v:
Nature, vol 602, iss 7898
Nature
Nature
Integration of sensory and molecular inputs from the environment shapes animal behaviour. A major site of exposure to environmental molecules is the gastrointestinal tract, in which dietary components are chemically transformed by the microbiota1 and
Autor:
Hidetoshi Hayashi, Yuuri Hashimoto, Kenji Hirotani, Kazuko Sakai, Hiroki Goto, Hisato Kawakami, Kazuhiko Nakagawa, Maki Kobayashi, Osamu Maenishi, Masanori Funabashi, Masayuki Takeda, Kazuto Nishio, Ryoto Yoshimoto, Takashi Kagari, Junko Tanizaki, Kaoru Tanaka, Kimio Yonesaka
Publikováno v:
Annals of Oncology. 32:S296